In this issue:
OS and intracranial control in limited-stage SCLC with prophylactic cranial irradiation
Pembrolizumab in patients with recurrent or metastatic SCLC
Effect of BMI on OS in atezolizumab-treated advanced NSCLC patients
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified NSCLC
Non-squamous NSCLC patient-reported outcomes following pembrolizumab + chemotherapy
Nivolumab for advanced, previously treated squamous NSCLC
Continuation maintenance bevacizumab + pemetrexed in advanced nonsquamous NSCLC
Pembrolizumab in NSCLC patients with performance status 2
First-line albumin-bound paclitaxel + gemcitabine in advanced squamous cell lung cancers
ASCO guideline for lung cancer surveillance after curative-intent therapy
ctDNA mutations as a diagnostic and prognostic biomarker for lung cancer
Please login below to download this issue (PDF)